Yingcheng Wu

List of Publications by Year
in descending order

29 papers	947 citations	687363 13 h-index	526287 27 g-index
31 all docs	31 docs citations	31 times ranked	965 citing authors

#	Article	IF	Citations
1	Spatiotemporal Immune Landscape of Colorectal Cancer Liver Metastasis at Single-Cell Level. Cancer Discovery, 2022, 12, 134-153.	9.4	286
2	Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma. Cancer Cell, 2022, 40, 70-87.e15.	16.8	120
3	Spatial omics: Navigating to the golden era of cancer research. Clinical and Translational Medicine, 2022, 12, e696.	4.0	53
4	Potential Biomarkers for Liver Cancer Diagnosis Based on Multi-Omics Strategy. Frontiers in Oncology, 2022, 12, 822449.	2.8	12
5	Single-cell transcriptomic analysis suggests two molecularly distinct subtypes of intrahepatic cholangiocarcinoma. Nature Communications, 2022, 13, 1642.	12.8	40
6	Decoding the complexity of metastasis. Cancer Biology and Medicine, 2022, 19, 1-5.	3.0	4
7	The endoribonuclease N4BP1 prevents psoriasis by controlling both keratinocytes proliferation and neutrophil infiltration. Cell Death and Disease, 2021, 12, 488.	6.3	11
8	Multi‐omics analysis reveals the functional transcription and potential translation of enhancers. International Journal of Cancer, 2020, 147, 2210-2224.	5.1	11
9	SPACE: a web server for linking chromatin accessibility with clinical phenotypes and the immune microenvironment in pan-cancer analysis. Cellular and Molecular Immunology, 2020, 17, 1294-1296.	10.5	3
10	Identification of prognostic risk factors for pancreatic cancer using bioinformatics analysis. PeerJ, 2020, 8, e9301.	2.0	9
11	Wide‐ranging analysis of survival‐related alternative splicing events in invasive breast carcinoma. Oncology Letters, 2020, 20, 1866-1878.	1.8	1
12	Super-enhancers modulate interleukin-6 expression and function in cancers. Translational Cancer Research, 2020, 9, 5555-5565.	1.0	1
13	Pan-Cancer Analysis Reveals Disrupted Circadian Clock Associates With T Cell Exhaustion. Frontiers in Immunology, 2019, 10, 2451.	4.8	69
14	The C-terminal low-complexity domain involved in liquid–liquid phase separation is required for BRD4 function in vivo. Journal of Molecular Cell Biology, 2019, 11, 807-809.	3.3	8
15	Survival-Associated Alternative Splicing Events in Pan-Renal Cell Carcinoma. Frontiers in Oncology, 2019, 9, 1317.	2.8	8
16	A Tumor-Specific Super-Enhancer Drives Immune Evasion by Guiding Synchronous Expression of PD-L1 and PD-L2. Cell Reports, 2019, 29, 3435-3447.e4.	6.4	33
17	Comprehensive transcriptome profiling in elderly cancer patients reveals aging‐altered immune cells and immune checkpoints. International Journal of Cancer, 2019, 144, 1657-1663.	5.1	21
18	HPV shapes tumor transcriptome by globally modifying the pool of RNA binding protein-binding motif. Aging, 2019, 11, 2430-2446.	3.1	14

#	Article	IF	Citations
19	The identification of gene signature and critical pathway associated with childhood-onset type 2 diabetes. PeerJ, 2019, 7, e6343.	2.0	4
20	Correlation between sex and efficacy of immune checkpoint inhibitors (<scp>PD</scp>â€‘1 and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70	5.1	85
21	EphA2 chimeric antigen receptor-modified T cells for the immunotherapy of esophageal squamous cell carcinoma. Journal of Thoracic Disease, 2018, 10, 2779-2788.	1.4	27
22	The effectiveness of PD-1 inhibitors in non-small cell lung cancer (NSCLC) patients of different ages. Oncotarget, 2018, 9, 7942-7948.	1.8	27
23	A comprehensive competitive endogenous RNA network pinpoints key molecules in diabetic retinopathy. Molecular Medicine Reports, 2018, 19, 851-860.	2.4	8
24	C-terminal binding proteinâ€‘2 mediates cisplatin chemoresistance in esophageal cancer cells via the inhibition of apoptosis. International Journal of Oncology, 2018, 53, 167-176.	3.3	11
25	Comparison between PDâ€‘1/PDâ€‘L1 inhibitors (nivolumab, pembrolizumab, and atezolizumab) in pretreated NSCLC patients: Evidence from a Bayesian network model. International Journal of Cancer, 2018, 143, 3038-3040.	5.1	11
26	Orchestrating a biomarker panel with lncRNAs and mRNAs for predicting survival in pancreatic ductal adenocarcinoma. Journal of Cellular Biochemistry, 2018, 119, 7696-7706.	2.6	17
27	The clinical value of combination of immune checkpoint inhibitors in cancer patients: A metaâ€‘analysis of efficacy and safety. International Journal of Cancer, 2017, 141, 2562-2570.	5.1	35
28	The efficacy of chimeric antigen receptor (CAR) immunotherapy in animal models for solid tumors: A systematic review and meta-analysis. PLoS ONE, 2017, 12, e0187902.	2.5	1
29	The revolution of lung cancer treatment: from vaccines, to immune checkpoint inhibitors, to chimeric antigen receptor T therapy. Biotarget, 0, 1, 7-7.	0.5	11